StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NKT-R.BK$3.92+0.00%
Fair $3.92+0.0%

NKT-R.BK

Nakornthon Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$3.92

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $3.92Fund rank 28/100 · Data gapFallback financials|
SA 42/C
F-Score: 5/9
Margin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $104.0M · quality 49.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 23/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

42/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Operating margin has declined for 3 consecutive years
Thesis & Journal · NKT-R.BKLocal privado en este navegador · Nakornthon Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.1B

P/E

10.6x

↓

EV/EBITDA

4.8x

↓

ROE

9.7%

↑

Gross Margin

28.4%

↓

Debt/Equity

0.04

↓
52-Week Range$4
$4$4

TradingView lightweight chart

NKT-R.BK price, volumen y niveles de valoración

Último $3.920Periodo +0.0%
Fair value: $3.920

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+0.8%

FCF CAGR

—

FCF margin

-27.8%

FCF / Net income

-2.82x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.99B · net income $195.4M · FCF $-551.8M

2022-FY → 2025-FY

Gross margin

28.4%-4.1% pts

Operating margin

13.0%-7.6% pts

Net margin

9.8%-6.7% pts

FCF margin

-27.8%-38.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.99B$1.99B$1.99B$2.00B$1.94B
Net Income$195.4M$195.4M$233.7M$282.3M$320.9M
EBITDA$394.0M$394.0M$428.5M$491.1M$505.7M
EPS0.370.370.580.530.60
Gross Margin28.4%28.4%29.5%30.8%32.5%
Operating Margin13.0%13.0%15.0%17.9%20.6%
Net Margin9.8%9.8%11.8%14.1%16.6%
Balance Sheet
Debt/Equity0.040.040.120.05—
Current Ratio1.771.77———
Cash Flow
Free Cash Flow$-551.8M$-551.8M$104.0M$206.6M$209.7M
Returns
ROE9.7%9.7%12.1%18.3%23.5%
Valuation
P/E10.5910.59———
EV/EBITDA4.784.78———
P/B1.041.04———
Growth & Yield
Revenue Growth0.0%0.0%-0.9%3.4%—
EPS Growth-36.2%-36.2%9.9%-12.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-2.0%

fácil

EPS terminal req.

$0.35

Spread vs growth

-34.2%

5Y implied EPS CAGR

2.6%

fácil

EPS terminal req.

$0.42

Spread vs growth

-38.8%

10Y implied EPS CAGR

6.2%

razonable

EPS terminal req.

$0.68

Spread vs growth

-42.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

6.8x → 10.6x

EPS bridge

0.58 → 0.37

Residual

-20.5%

EPS growth-36.2%
Multiple rerating+56.8%
Dividend+0.0%
Residual / FX / buybacks / cross-term-20.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.